While Sanofi’s diet drug Acomplia (rimonabant) remains stalled at the FDA, a potential competitor currently in phase III trials, Merck’s MK-0364, now has an official generic name: Taranabant.
Taranabant is Merck’s cannabinoid-1 (CB-1) receptor inverse agonist, and from reports we periodically receive from participants in the phase III trial of this diet drug, taranabant is as effective for weight loss as rimonabant with fewer side effects.
While Merck has not reported interim results from the phase III trial, which obviously could prove different from the anecdotal reports we receive, the company has said the pill was well tolerated in extensive phase II trials and that it plans to seek FDA approval for Taranabant next year.
Meanwhile Pfizer, which also has a CB-1 receptor antagonist in phase III trials, has as of yet not moved forward with a name for the diet drug known only as CP-945598.
Merck and Pfizer both will be watching intently the coming June FDA Acomplia (rimonabant) advisory panel meeting on rimonabant, which is expected to focus heavily on safety issues associated with this novel class of drugs that affect receptors in the brain.
Метки:
diet drug,
drug,
fda,
generic,
loss,
report,
results,
side effects,
weight,
Zimulti
Посмотрите также
- Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
- Diet Drug Taranabant Produces Weight Loss at One-Tenth the Acomplia Dosage
Merck diet drug taranabant, which targets the same CB-1 receptor as Sanofi’s obesity treatment Acomplia (rimonabant) , also produces psychiatric side effects but results in almost-as-good weight loss at one-tenth the dosage, according to study results presented to the American College of Cardiology.
Merck said one-year results from a two-year [...]
- Study: Highly Encouraging Two-Year Trial Results Reported for Acomplia
The new diet drug rimonabant (Acomplia) helped people lose significantly more weight than a placebo in a two-year clinical trial, the largest of the studies of this drug conducted to date, according to researchers.
The study also showed that while most Acomplia (rimonabant) of the weight loss occured [...]
- Side-Effects May Be Similar to Rimonabant ( Acomplia/Zimulti)
Diet drug taranabant, a CB-1 receptor inverse agonist which many hoped would have a better side-effect profile than Sanofi’s CB-1 receptor antagonist rimonabant Rimonabant ( Acomplia/Zimulti), may have similar problems, according to an analyst for investment bank Leerink Swann.
Analyst Aileen Salares, in a research report based on an abstract of [...]
- Sanofi-Aventis Seeks to Shut Down News Coverage by the Acomplia Report
Sanofi-Aventis, developer of the much touted diet drug Acomplia (rimonabant) , has announced its intention to try and shut down the independent Acomplia Report, denying hundreds of thousands of obese and overweight individuals this unbiased source of news about the drug and efforts to bring it to market.
In emails [...]
- Sanofi Holds Little Hope For Early U.S. Sale of Acomplia / Zimulti (Rimonabant)
Diet drug Acomplia / Zimulti ( rimonabant ) has now been taken by more than 200,000 obese and overweight patients in Europe and a handful of other countries, but Sanofi-Aventis offered no encouragement on Aug. 1 to those hoping to see it approved for early sale in the United States Rimonabant [...]
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.